Bailard Inc. Sells 48,838 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Bailard Inc. lowered its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.8% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 673,507 shares of the biopharmaceutical company’s stock after selling 48,838 shares during the period. Gilead Sciences comprises 1.6% of Bailard Inc.’s holdings, making the stock its 12th largest holding. Bailard Inc. owned about 0.05% of Gilead Sciences worth $54,561,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of GILD. OFI Invest Asset Management acquired a new position in Gilead Sciences in the third quarter valued at $26,000. Tompkins Financial Corp lifted its holdings in Gilead Sciences by 223.1% in the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 241 shares during the period. Fortitude Family Office LLC acquired a new position in Gilead Sciences in the fourth quarter valued at $29,000. Rakuten Securities Inc. acquired a new position in Gilead Sciences in the fourth quarter valued at $33,000. Finally, Financial Connections Group Inc. acquired a new position in Gilead Sciences in the fourth quarter valued at $40,000. Institutional investors own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the sale, the insider now directly owns 96,304 shares in the company, valued at approximately $7,026,339.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.29% of the stock is currently owned by corporate insiders.

Gilead Sciences Stock Performance

GILD traded up $0.05 during midday trading on Wednesday, reaching $67.08. The company had a trading volume of 8,464,533 shares, compared to its average volume of 7,317,518. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43. The stock has a market cap of $83.52 billion, a PE ratio of 14.91, a P/E/G ratio of 0.96 and a beta of 0.19. Gilead Sciences, Inc. has a 12-month low of $65.90 and a 12-month high of $87.86. The business has a 50-day moving average price of $71.56 and a two-hundred day moving average price of $76.39.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). The company had revenue of $7.12 billion during the quarter, compared to analysts’ expectations of $7.10 billion. Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. The firm’s revenue was down 3.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.67 earnings per share. On average, sell-side analysts expect that Gilead Sciences, Inc. will post 6.28 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 28th. Investors of record on Friday, March 15th were paid a dividend of $0.77 per share. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.75. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.59%. The ex-dividend date was Thursday, March 14th. Gilead Sciences’s dividend payout ratio is presently 68.44%.

Analysts Set New Price Targets

GILD has been the subject of several research analyst reports. UBS Group decreased their price target on shares of Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a research note on Wednesday, April 17th. Wells Fargo & Company decreased their price target on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a research note on Monday, March 4th. Oppenheimer reaffirmed an “outperform” rating and issued a $105.00 price target on shares of Gilead Sciences in a research note on Friday, April 19th. Mizuho decreased their price target on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating for the company in a research note on Thursday, February 22nd. Finally, HSBC raised shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price target for the company in a research note on Wednesday. Ten equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $84.57.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.